title: Effects of sertraline on experimental mouse models of psychosis.
abstract: OBJECTIVE
  To study the effects of sertraline on neuroleptic-induced catalepsy, apomorphine-induced climbing behavior, and amphetamine or MK-801-induced locomotor activities in female Swiss albino mice weighing 30-35 g.
  
  
  METHODS
  This study was performed in the Department of Pharmacology, Eskisehir Osmangazi University, Eskisehir, Turkey between April 2008 and January 2010. Catalepsy was induced by haloperidol (1 mg/kg intraperitoneally [ip]). Apomorphine (1.5 mg/kg subcutaneously [sc]) was used for studying climbing behavior, and d-amphetamine (30 mg/kg ip) or MK-801 (0.3 mg/kg ip) was used for testing locomotor activities. Eight animals were used in each group. Sertraline (10 mg/kg ip) was injected either acutely, or over 5 days of repeated treatment.
  
  
  RESULTS
  Sertraline inhibited catalepsy and climbing behavior when it was used for 5 days in repeated doses, while it augmented amphetamine-induced locomotor activity. It reduced MK-801-induced stereotypic movements, but did not significantly affect amphetamine-induced stereotypic movements when used in a single dose or repeated doses.
  
  
  CONCLUSIONS
  These results suggest that sertraline, a selective serotonin reuptake inhibitor may be a beneficial adjuvant drug during psychosis therapy.
authors.affiliation: Department of Pharmacology, School of Medicine, Eskisehir Osmangazi University, Turkey.
authors.forename: Ugur
authors.initials: U
authors.lastname: Bilge
authors.forename: Kevser
authors.initials: K
authors.lastname: Erol
mesh_terms: D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001058:Apomorphine / Q000494:pharmacology; D002375:Catalepsy / Q000139:chemically induced / Q000188:drug therapy*; D003913:Dextroamphetamine / Q000494:pharmacology; D004195:Disease Models, Animal; D016291:Dizocilpine Maleate / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006220:Haloperidol / Q000009:adverse effects; D051379:Mice; D009043:Motor Activity / Q000187:drug effects*; D011618:Psychotic Disorders / Q000188:drug therapy*; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D020280:Sertraline / Q000494:pharmacology / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D000928:Antidepressive Agents; D001058:Apomorphine; D003913:Dextroamphetamine; D016291:Dizocilpine Maleate; D006220:Haloperidol; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline